These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors. Merlo A; Turrini R; Bobisse S; Zamarchi R; Alaggio R; Dolcetti R; Mautner J; Zanovello P; Amadori A; Rosato A J Immunol; 2010 May; 184(10):5895-902. PubMed ID: 20385879 [TBL] [Abstract][Full Text] [Related]
6. Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy. Feuchtinger T; Lang P; Hamprecht K; Schumm M; Greil J; Jahn G; Niethammer D; Einsele H Exp Hematol; 2004 Mar; 32(3):282-9. PubMed ID: 15003314 [TBL] [Abstract][Full Text] [Related]
7. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389 [TBL] [Abstract][Full Text] [Related]
8. Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein. Turcanová V; Höllsberg P J Med Virol; 2004 Apr; 72(4):635-45. PubMed ID: 14981767 [TBL] [Abstract][Full Text] [Related]
9. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy. Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498 [TBL] [Abstract][Full Text] [Related]
10. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide. Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491 [TBL] [Abstract][Full Text] [Related]
11. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009 [TBL] [Abstract][Full Text] [Related]
12. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells. Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833 [TBL] [Abstract][Full Text] [Related]
13. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy. Lugthart G; Albon SJ; Ricciardelli I; Kester MG; Meij P; Lankester AC; Amrolia PJ J Immunother; 2012 Jan; 35(1):42-53. PubMed ID: 22130159 [TBL] [Abstract][Full Text] [Related]
15. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy. Li J; Mookerjee B; Wagner J J Immunother; 2008 Jan; 31(1):81-8. PubMed ID: 18157015 [TBL] [Abstract][Full Text] [Related]
16. Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma. Wheatley GH; McKinnon KP; Iacobucci M; Mahon S; Gelber C; Lyerly HK Surgery; 1998 Aug; 124(2):171-6. PubMed ID: 9706135 [TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of Epstein-Barr virus-specific human CD4+ T lymphocyte clones. Honda S; Takasaki T; Okuno K; Yasutomi M; Kurane I Acta Virol; 1998 Nov; 42(5):307-13. PubMed ID: 10358731 [TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075 [TBL] [Abstract][Full Text] [Related]
19. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant. Regn S; Raffegerst S; Chen X; Schendel D; Kolb HJ; Roskrow M Bone Marrow Transplant; 2001 Jan; 27(1):53-64. PubMed ID: 11244438 [TBL] [Abstract][Full Text] [Related]
20. A sealed and unbreached system for purification, stimulation, and expansion of cytomegalovirus-specific human CD4 and CD8 T lymphocytes. Li Pira G; Bottone L; Ivaldi F; Pelizzoli R; Risso M; Tripodi G; Manca F Transfusion; 2006 Dec; 46(12):2053-62. PubMed ID: 17176316 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]